HBOT Conversations:
Dr. Peter Canaday (Part 1)
Dr. Peter Canaday has published work in Applied Physiology, Respiratory Medicine, and Diagnostic Radiology. He has presented at National (USA) and International meetings, and his research supported the eventual FDA approval of a new medical imaging device incorporating digital X-ray tomosynthesis. He has sat on National, State, and Local advisory committees, and given testimony at the State Legislative level in the USA.
Dr. Canaday’s experience with Hyperbaric Oxygen Therapy dates back to the 1980s when he studied HBOT under Dr. Eric Kindwall, “The Father of Hyperbaric Medicine”. Dr. Canaday also co-founded the Hyperbaric Medicine Department at St. Anthony Hospital in Lakewood, Colorado.
From 2007, Dr. Canaday spent time in community radiology practices before settling in New Zealand in 2013 as a Consultant Radiologist. Since 2016, he was employed at a Midlands region DHB and served as Head of Department before retiring in March 2021.
Watch the Podcast
HBOT News welcomes Dr. Peter Canaday. Dr. Canaday now lives primarily in New Zealand, but his history with medicine and Hyperbaric Oxygen Therapy dates back over 40 years to the United States.
In this HBOT News Network Conversations, Dr. Canaday spends the first several minutes providing listeners with his biography and medical background. He also dives into his experience with Hyperbaric Oxygen Therapy in the 1980s.
The subject of PTSD and recent Hyperbaric research arises, and Dr. Canaday expands on the topic by referencing two research articles from Dr. Paul G. Harch –
Dr. Canaday further explains, “There is a recruitment of the anti-inflammatory enzymes and a suppression of the pro-inflammatory enzymes that can be achieved through even these lower pressure units. And so we’re beginning to see now the potential mechanism for which Hyperbaric Therapy, whether with or without oxygen, may be effective.”
The remainder of this HBOT News Conversation is specific to the topic of COVID-19. di Girolamo starts the conversation discussing the struggles for long-hauler COVID patients and the growing number of vaccine injuries as a result of the COVID-19 vaccine. Dr. Canaday agrees that the scientific inquiry for COVID-19 and the available information for associated vaccines has been widely suppressed. He continues that even the data which represent conclusions from peer-reviewed literature has been simply ignored, or set aside without discussion.
In response, Dr. Canaday provides viewers with direct links on how they can learn more about some of the data and information he’s shared with the public regarding the COVID-19 vaccine roll-outs:
Dr Peter Canaday – Pfizer Vaccine Discussion At The Town Hall
Courageous Convos with Special Guest Peter Canaday
Voices of Freedom on Odysee : search Peter Canaday
Dr. Canaday’s HBOT News Conversations is a two part series. Part 2 will air on Friday, December 16, 2022.
This HBOT News Conversation was filmed on October 4, 2022
Guest
Dr. Peter Canaday
Following completion of medical school at the University of Massachusetts in 1976, Dr. Peter Canaday took up training as an Internal Medicine specialist at the University of Michigan, followed by sub-specialist training in Respiratory and Intensive Care at the University of North Carolina. He began his medical career in a busy trauma hospital in Denver, Colorado in 1981 and practiced for 12 years. During his time there, he managed many of the types of patients now seen with severe COVID-19, co-founded a sleep disorders laboratory and a hyperbaric medicine department. As well, he participated in a dozen committee assignments, and rose to Chairman of the Department of Internal Medicine. In 1993, Dr Canaday changed career and completed training as a Radiologist at the University of Wisconsin in 1997. During an 8-year period at Creighton University Medical School in Nebraska, he became tenured as an Assistant Professor of Radiology, and head of the section of Pulmonary Radiology. He also served on or chaired over a dozen hospital and medical school committees and was appointed Clinical Coordinator for the Radiology Department during his time there. Dr Canaday has also published work in applied physiology, respiratory medicine, and diagnostic radiology, has presented at national (USA) and international meetings, and his research supported the eventual FDA approval of a new medical imaging device incorporating digital X-ray tomosynthesis. He has sat on national, state, and local level advisory committees and given testimony at the state legislative level in the USA. From 2007, Dr Canaday spent time in community radiology practices before settling in New Zealand in 2013 as a Consultant Radiologist. Since 2016, he was employed at the Taranaki District Health Board and served as Head of Department before retiring in March 2021.
Subscribe Now, It’s Free!
Recent HBOT News
International Survey Regarding the Use of Rehabilitation Modalities in Horses.
Abstract: To define which biologic, electrophysical and other modalities are used in horses for injury or performance issues, a questionnaire regarding 38 modalities was distributed to eight veterinary groups. A total of 305 complete or partial responses were obtained...
Clinical Trial – Effects of Repetitive Hyperbaric Oxygen Therapy in Patients With Acute Ischaemic Stroke
Background and Rationale:
Cerebrovascular disease is always ranked at the top causes of death and most of hospitalized
acute stroke patients have ischemic stroke [1].
Although the mortality rate of acute ischemic stroke is less than that of hemorrhagic stroke
[1], it still results in patient disabilities and complications that often lead to
significant costs to individuals, families, and society.
Traditional treatment for acute ischemic stroke includes thrombolytic therapy by injecting
tissue plasminogen activator (t-PA) within three hours after onset of symptoms [2],
antiplatelets and/or anticoagulant agents administered within the first 48 hours. Clinically,
the narrow time window of thrombolytic therapy and coexisting contraindications limit the use
of t-PA [2]. Thus, searching for an effective supplemental treatment for acute ischemic
stroke is imperative.
Hyperbaric oxygen therapy (HBOT) is valuable in treating acute carbon monoxide poisoning
[3,4], air or gas embolism [5], facilitating wound healing [6] and has been used as an
adjuvant treatment for many neurological disorders that need further study as concussion [7]
, stroke [8,9], cerebral palsy [ 10],traumatic brain injury [ 11], cerebral air embolism
[12], Autism [13] and multiple sclerosis [14].
Indications of hyperbaric oxygen therapy recommended by undersea and hyperbaric medical
society (UHMS) [15] are 1.air or gas embolism [5], 2.carbon monoxide poisoning [3,4],
3.clostridial myositis and myonecrosis [16], 4.crush injury, compartment syndrome and other
acute traumatic ischemias [17], 5.decompression sickness [18], 6.arterial insufficiencies
[19], 7.severe anemia [20], 8.intracranial abscess [21], 9.necrotizing soft tissue infections
[22],10. refractory osteomyelitis [23], 11.delayed radiation injury [24], 12.compromised
grafts and flaps [25], 13.acute thermal burn injury [26] and 14.idiopathic sudden
sensorineural hearing loss [27].
Known mechanisms of HBOT-induced neuroprotection include enhancing neuronal viability via
increased tissue oxygen delivery to the area of diminished blood flow, reducing brain edema,
and improving metabolism after ischemia [28,29]. Furthermore, a recent study performed on a
rat suggested that upregulation of the expression of glial derived neurotrophic factor (GDNF)
and nerve growth factor (NGF) might underlie the effect of HBOT [30].
The effectiveness of use of Hyperbaric oxygen therapy in human ischemic stroke is still
controversial that need further evaluation.
Clinical Trial – Effect of Adjuvant Hyperbaric Oxygen Therapy on Bells Palsy Outcome
This is a randomized, single blinded, non-placebo controlled that will compare one group of
Bells Palsy patients receiving the current standard of care including oral corticosteroids
and oral antivirals against an experimental group receiving the current standard of care in
addition to hyperbaric oxygen therapy. Outcome assessment will be based on both objective
analyses of facial movements as well as subjective quality of life scales.